Gaboxadol
Gaboxadol is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target gamma-aminobutyric acid receptor subunit alpha-3, gamma-aminobutyric acid receptor subunit alpha-6, gamma-aminobutyric acid receptor subunit rho-1, gamma-aminobutyric acid receptor subunit rho-2, gamma-aminobutyric acid receptor subunit rho-3, gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-1, gamma-aminobutyric acid receptor subunit alpha-4, gamma-aminobutyric acid receptor subunit delta, and gamma-aminobutyric acid receptor subunit alpha-5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 2 | 13 | — | — | 15 |
| Syndrome | D013577 | — | — | 1 | 4 | 2 | — | — | 7 |
| Angelman syndrome | D017204 | Orphanet_72 | Q93.51 | 1 | 1 | 2 | — | — | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fragile x syndrome | D005600 | — | Q99.2 | 1 | 3 | — | — | — | 4 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gaboxadol |
| INN | gaboxadol |
| Description | 4,5,6,7-Tetrahydroisoxazolo(5,4-c)pyridin-3-ol is an oxazole. |
| Classification | Small molecule |
| Drug class | analgesics (mixed opiate receptor agonists/antagonists); gabamimetics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Oc1noc2c1CCNC2 |
Identifiers
| PDB | — |
| CAS-ID | 64603-91-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL312443 |
| ChEBI ID | 34373 |
| PubChem CID | 3448 |
| DrugBank | — |
| UNII ID | K1M5RVL18S (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GABRA3
GABRA3
GABRA6
GABRA6
GABRR1
GABRR1
GABRR2
GABRR2
GABRR3
GABRR3
GABRA2
GABRA2
GABRA1
GABRA1
GABRA4
GABRA4
GABRD
GABRD
GABRA5
GABRA5
Organism
Homo sapiens
Gene name
GABRA3
Gene synonyms
NCBI Gene ID
Protein name
gamma-aminobutyric acid receptor subunit alpha-3
Protein synonyms
GABA(A) receptor subunit alpha-3, GABA(A) receptor, alpha 3, gamma-aminobutyric acid (GABA) A receptor, alpha 3, gamma-aminobutyric acid type A receptor alpha3 subunit, gamma-animobutyric acid (GABA) A receptor, alpha 3
Uniprot ID
Mouse ortholog
Gabra3 (14396)
gamma-aminobutyric acid receptor subunit alpha-3 (P26049)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,031 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use